Irbesartan Bristol Laboratories (Irbesartan)

Irbesartan selectively antagonises the angiotensin II type 1 (AT1) receptor. By preventing angiotensin II from binding, it reduces vasoconstriction and aldosterone release, leading to relaxed blood vessels, lower peripheral resistance, decreased sodium and water retention, and ultimately a reduction in arterial blood pressure.

The appropriate dose of Irbesartan Bristol Laboratories is determined by the prescribing clinician based on the individual’s blood pressure, kidney function, and overall health status. Dosage may be adjusted during treatment to achieve target blood pressure while minimizing side effects.

Irbesartan is classified as Pregnancy Category D, indicating evidence of fetal risk and it should not be used during pregnancy. Women of child‑bearing potential should use effective contraception. Limited data are available for breastfeeding; therefore, the drug is generally not recommended while nursing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Irbesartan belongs to the angiotensin II receptor blocker (ARB) class, which offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angio‑edema. Compared with calcium‑channel blockers or diuretics, ARBs provide additional renal protection, especially in patients with diabetes, making Irbesartan a preferred option in such populations.

Irbesartan tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light, and store out of reach of children. Do not refrigerate or freeze the product.

Irbesartan is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and not alter the timing without medical advice.

The most serious risks include angio‑edema (swelling of the face, lips, tongue or throat), severe hyperkalaemia, acute renal failure, and marked hypotension. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden loss of kidney function, or a rapid drop in blood pressure.

Irbesartan should not be used by individuals who are pregnant, have known hypersensitivity to Irbesartan or any ARB component, or have severe hepatic impairment without careful monitoring. Caution is also advised in patients with bilateral renal artery stenosis or those taking other medications that raise potassium levels.